Lung Cancer News and Research

Latest Lung Cancer News and Research

Synthetic cannabinoid could treat pain in diabetes patients

Oral synthetic cannabinoid nabilone may be effective for treating diabetic peripheral neuropathic pain, a study shows.

8 Nov 2012

BMI may not be best measure for estimation of cancer risk

A study by researchers at Albert Einstein College of Medicine of Yeshiva University suggests that body mass index (BMI)-the most commonly used weight-for-height formula for estimating fatness-may not be the best measure for estimating disease risk, and particularly the risk of certain types of cancer. The study was published today in the online edition of the American Journal of Epidemiology.

8 Nov 2012

Synta announces interim results from docetaxel Phase 2b/3 trial on NSCLC

Synta Pharmaceuticals Corp. announced today that interim results from the Phase 2b/3 GALAXY trial will be presented at the Chemotherapy Foundation Symposium in New York City on Friday, November 9 during the 11:45 a.m. session on new agents for lung cancer. Presenting this data at the conference will be Dr. Suresh Ramalingham, Professor, Hematology & Medical Oncology, and Director, Translational Thoracic Malignancies Program, of the Winship Cancer Institute of Emory University.

7 Nov 2012

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies.

7 Nov 2012

Measuring blood levels of hs-CRP could help identify men at increased risk for death from cancer

Measuring blood levels of high-sensitive C-reactive protein, an important marker of inflammation, in apparently cancer-free men could potentially help identify those at increased risk for death from cancer, in particular lung cancer, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

7 Nov 2012

Neonatal TSH screening insensitive for iodine insufficiency

Measuring levels of neonatal thyroid-stimulating hormone may not be sufficiently sensitive for inferring the extent of iodine deficiency in a given population, study results suggest.

5 Nov 2012

Sausalito Shine a Light on Lung Cancer Vigil to be held on Nov. 13 in the U.S.

This event will shine a light on one of the United States' most deadly and overlooked epidemics. Lung cancer kills approximately 160,000 Americans annually - more than breast, prostate and colon cancers combined - and has the worst survival rate of all cancers.

3 Nov 2012

Radiosurgery alone can achieve local control of brain metastases

Radiosurgery to the surgical cavity without whole-brain radiotherapy achieves good rates of local control in patients with brain cancer metastases, a study has shown.

2 Nov 2012

Driving up CVD event risk in diabetes

Professional drivers who have diabetes are at a significantly increased risk for a cardiovascular disease event compared with individuals with other occupations, report researchers.

2 Nov 2012

$Denosumab gives FREEDOM to heal fractures$

Denosumab gives FREEDOM to heal fractures

Results from the FREEDOM trial indicate that fracture healing is not impaired in women with osteoporosis who use the antiresorptive therapy denosumab.

2 Nov 2012

Virginia G. Piper, TESARO announce initiation of TSR-011 clinical trial for advanced cancer

TESARO, Inc. announced today that the first clinical trial of its proprietary Anaplastic Lymphoma Kinase (ALK) inhibitor, TSR-011, has commenced with the dosing of the first patient at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen).

2 Nov 2012

CD22 protein could prove to be important new target for anti-cancer therapy

A team of UC Davis investigators has discovered a protein on the surface of lung cancer cells that could prove to be an important new target for anti-cancer therapy. A series of experiments in mice with lung cancer showed that specific targeting of the protein with monoclonal antibodies reduced the size of tumors, lowered the occurrence of metastases and substantially lengthened survival time.

2 Nov 2012

Better access to fresh, local food urged for underprivileged families

Initiatives that improve the ability of socially disadvantaged families to obtain local produce are sorely needed, say US researchers.

1 Nov 2012

Primary care improvement program shows benefits of collaboration

A collaborative primary care program aimed at enhancing provision for chronic diseases, patient self-management, access, and Aboriginal healthcare has shown improvement across the vast majority of measures, Australian study findings indicate.

1 Nov 2012

Teva third quarter 2012 net revenues increase 14% to $5.0 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended September 30, 2012.

1 Nov 2012

Varian highlights numerous lung cancer treatment systems at ASTRO meeting

Varian Medical Systems highlighted the company's technologies for the non-invasive treatment of lung cancer at the 54th annual meeting of the American Society for Radiation Oncology (ASTRO) in Boston this week.

1 Nov 2012

Biomarker discovery offers hope for lung cancer blood test

Blood levels of a variant form of the nuclear matrix protein Ciz1 are significantly higher in individuals with early- and late-stage lung cancer than in lung cancer-free individuals, researchers report.

31 Oct 2012

Radiation therapy protocol deviations associated with increased risk of treatment failure and overall mortality

Radiation therapy protocol deviations in clinical trials are associated with increased risk of treatment failure and overall mortality, according to a study entitled, “Radiotherapy Protocol Deviations are Associated with Inferior Clinical Outcomes: A Meta-analysis of Cooperative Group Clinical Trials” to be presented today at the 54th annual meeting of the American Society for Radiation Oncology (ASTRO) in Boston, MA.

30 Oct 2012

Array BioPharma first quarter 2013 revenue decreases to $15.8 million

Array BioPharma Inc. today reported results for the first quarter of its fiscal year ending June 30, 2013.

30 Oct 2012

Positive results from Celldex’s CDX-1401 Phase 1 study on solid tumors

Celldex Therapeutics, Inc. today announced positive results demonstrating promising clinical effects in a Phase 1 study of CDX-1401 in solid tumors in combination with the toll-like receptor (TLR) agonists resiquimod and/or Poly ICLC.

30 Oct 2012